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Frédéric Y BoisAbstract
This first special issue of In Silico Pharmacology focuses on computational pharmacokinetics since they are an
important part of integrated applications in computational pharmacology. The important topics of model structure,
model parameterization, improved organ description, and modeling of drug-drug interactions are covered. They are
actually at the crossroads between several emerging disciplines which will shape the future of therapeutic
treatments and public health.
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We have chosen to focus this first special issue of In Silico
Pharmacology on computational pharmacokinetics. In our
view, that was a logical step since pharmacokinetics are a
foundational part computational pharmacology.Main text
Pharmacokinetic (PK) modeling has come quite a long
way since it started in the fifties, to the point that we
know call it "computational pharmacokinetics". . . From
a branch of (statistical) modeling applied to PK, it has
become a sub-discipline of PK itself. The drive for that
mutation has clearly been the need to exceed the limits
of interpolation and parameter estimation provided by
statistical models (even if they were biologically moti-
vated, as compartment models can be) and to enter the
realm of extrapolations and predictions. That was a main
point of the last Paris talk given by the much regretted
L. Sheiner, a few years ago already.
Physiologically-based PK modeling (PBPK) is at the
heart of this evolution. Originally developed as a concep-
tual tool Teorell, e.g., (1937), applied for interspecies
extrapolation Dedrick et al., (1973), incubated and
refined for quite a while in the data poor environment of
environmental toxicology, it has really taken off during
the last 10 years when specialized software and param-
eter databases were made available. This issue of In
Silico Pharmacology offers clear illustrations of some of
the most active developments in this area.Correspondence: frederic.bois@utc.fr
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medium, provided the original work is properlyAt the heart of PBPK modeling, we find developments
in model structure and parameterization. Mastering the
various concepts and techniques used in PBPK modeling
is a challenge. The whole gamut of differential equation
development and solving, and practically all of the nu-
merical computation techniques, up to advanced sto-
chastic simulatios, are relevant. The major advantages,
for practitioners, of pre-coded general PBPK models
such as PKSimW (developed by Bayer TechnologyW) or
SimcypW are obvious: standardization, yet flexibility, ease
of use, hiding from user the (usually) unnecessary com-
putational details, focusing on substantive questions ra-
ther than spending time of coding and solving. Yet,
biology, or even PK, cannot be subsumed to the existing
models and an unlimited number of improvements are
possible. How to manage those, in a quality assurance
framework, is the major topic of the article by M. Jamei
et al. at SimcypW Jamei, (2013). While waiting for the
perfect model and databases, the developers of PKSimW
illustrate the power of Bayesian population analyses in
the context of PBPK modeling. Getting improved
parameter distributions, helping clinical data analysis,
and even making substantive inference and actual
discovery about a biological process are all demonstrated
Krauss et al., (2013). It is to me a great pleasure to see
our early contribution Gelman et al., (1996) to this line
of research finally comes of age.
At the frontiers of PBPK modeling lie two vast
research areas: virtual organ models and systems biol-
ogy. Only the future will tell us whether those two fields
merge and what happens to "PBPK" modeling per se in
that case. . . Meanwhile, we can probably usefully borrowAccess article distributed under the terms of the Creative Commons Attribution
y/2.0), which permits unrestricted use, distribution, and reproduction in any
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tually be somewhat illogical to invest in pharmacokinetic
research at the cell level without paying attention to the
way cells are organized in tissues and organs. To
pharmacokinetics, as sensitivity analyses tend to show,
the most important organ models to develop are those
related to inputs and outputs (the A, M and E in
ADME). This journal is expected to cover extensively all
those in the near future. Virtual organ models can also
receive specific applications in local pharmacokinetics,
physiology or pharmacology, without linking to PBPK.
This special issue features an important article on the
coupling of a detailed skin model to a PBPK model by
Procter and GambleW research laboratories Dancik
et al., (2013). It also illustrates one of the most import-
ant and sought for application of PBPK modeling Adler
et al., (2011): Quantitative in vitro to in vivo extrapolation
(QIVIVE). This is also a topic of the review paper by N.
Quignot Quignot, (2013) in the context of blood to tissue
barriers, and of the last paper from A. Owen's group
Siccardi et al., (2013). Quignot's paper actually returns us
back at some foundational issues in PBPK modeling. In a
way, barriers (and inter-molecular interactions) are such
stuff as PBPK models are made on. The question of bar-
riers, their identification and models, is in a sense a pre-
requisite to PBPK modeling. This question is actually
pressing for the proper construction of such models for
nanocarriers, for example.
Siccardi et al. paper, besides QIVIVE, presents another
important application of PBPK modeling: predicting
drug-drug interactions. This is directly linked to out last
frontier: systems biology. Metabolism has always been
the Achilles' heel of PBPK models. I have rarely seen
serious criticisms of a PBPK model but in that grey area
where sophisticated transport mechanistic modeling
meets the most simplistic assumptions about metabolism
(linear vs. Michaelis-Menten for short). The situation has
markedly improved during the last 10 years, for example in
SimcypW, but the interface between a drug (and a fortiori
several concurrently) and the molecular cell machinery, be
it for active transport, metabolism and early effects is a
totally open question and any advance in the area is most
welcome. The PKSimW sofware has a flexible answer
(MoBiW), and an alternative route via systems biology
markup language (SBML) models composition has been
proposed by us Bois, (2009). These developments are very
exciting as PBPK models are much called for in systems
biology models for handling circulating species.
Conclusion
Why "at a crossroads" in the title of this commentary?
PBPK modeling and computational pharmacokinetics in
general are, I think, approaching a "tipping point" at
which they can merge with either or both virtual bodymodeling or systems biology. We may well be at the very
place where the merging of all three will happen, for a
better understanding and predictions of our underlying
biology. I remember gazing with much curiosity and
excitment the covers and titles of "Theoretical Biology"
during my freshman year's. This was beyond my reach at
the time. . . But the excitement is still going on after all
these years, with added fun and a sense of progress. I
am convinced that the contributions to this journal will
continue to convey this ambivalent sense of both discov-
ery and achievement.
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